🧾 What This Document Is

This is a Securities Purchase Agreement filed as an exhibit to an 8-K report. Think of it as the detailed contract for a private investment deal. Connect Biopharma is selling new shares directly to a group of investors (not on the public stock market) to raise money quickly. This filing lays out all the legal terms, protections, and conditions for that sale.

🏢 What The Company Does

👉 In simple terms, Connect Biopharma is a clinical-stage biopharma company focused on developing new medicines for inflammatory and autoimmune diseases. They use T-cell biology to discover and develop treatments. Being "clinical-stage" means they are primarily in the research and trial phase, spending money to develop drugs that aren't generating revenue yet. They trade on the Nasdaq under the ticker CNTB.

💰 Financial Highlights of the Deal

• Shares Sold: 6,130,000 Ordinary Shares.
• Price Per Share: The exact "Per Share Purchase Price" is listed in a separate schedule (not in this main text), but it's set at a discount to the market price, which is typical for these deals.
• Total Potential Raise: The exact total isn't stated here, but it's calculated by multiplying 6.13 million shares by the per-share price.
• Closing Date: The deal was set to close on March 31, 2026.
• Placement Agents: Leerink Partners LLC and Cantor Fitzgerald & Co. helped arrange the deal and find the investors.

🚀 Key Moves & Deal Mechanics

This isn't a simple stock sale. It has specific rules:

• Private Placement: The shares are sold under an exemption from registration, meaning they are restricted and can't be sold freely to the public right away.
• Ownership Limits: Some investors elected a 9.99% or 14.99% cap on how much of the company they can own after the deal, to avoid certain regulatory hurdles.
• Lock-up Agreements: Company insiders (directors and key officers) agreed not to sell their own shares for a period, showing alignment with the new investors.
• Closing Conditions: The deal only goes through if the company's warranties are true, no major bad events happen, and the Nasdaq doesn't object to the new shares.

📦 Why Raise Money This Way? (The Cash Story)

Clinical-stage biopharma companies are cash-burning engines. They need continuous funding to pay for expensive clinical trials, research, and operations before they have an approved, revenue-generating drug. 👉 This raise provides immediate working capital to fund their pipeline, advance clinical trials, and cover general expenses. It's a faster, more certain way to get cash compared to a public offering, though it often comes at a lower price per share.

🔮 What's Next & Strategic Direction

• Fund the Pipeline: The primary use of proceeds will be to advance their drug candidates through clinical development.
• Regulatory Compliance: The company must file a report with the China Securities Regulatory Commission (CSRC) within three working days after closing, highlighting its operational ties to China.
• Continue as a Going Concern: This funding is crucial for the company to continue its operations and pursue its strategic goals.

⚖️ Big Picture: Strengths & Risks

👍 Strengths:

• Secured dedicated capital from institutional investors.
• Placement agents (Leerink, Cantor) add credibility.
• Lock-up agreements from insiders reduce near-term selling pressure.

⚠️ Risks & Considerations:

• Dilution: Existing shareholders' ownership percentage is reduced because new shares are created.
• Discount Pricing: Private placements typically happen at a discount to the market price, which can signal the company's need for cash.
• Pipeline Dependency: The company's future value is almost entirely dependent on the success of its clinical trials. Failure of a key drug candidate is a major risk.
• Regulatory Complexity: Operating with a significant presence in China adds layers of regulatory compliance (like the CSRC filing).

🧠 The Analogy

Imagine a promising but early-stage biotech startup is building a high-tech plane (a new drug). They've built the prototype but need money to buy fuel (fund trials) to see if it can actually fly (get FDA approval). This deal is like getting a group of specialized investors to buy fuel vouchers at a discount. The investors are betting the plane will fly and their vouchers will become valuable, but there's no guarantee the plane will leave the runway.

📇 Key Contacts & People

• Company Executives (for "Knowledge of the Company"):
  • Barry Quart, Pharm.D. (Named Executive)
  • David Szekeres (Named Executive)
  • Lisa Peraza (Named Executive)
• Placement Agents:
  • Leerink Partners LLC
  • Cantor Fitzgerald & Co.
• Legal Counsel:
  • Latham & Watkins LLP (U.S. and Hong Kong counsel)
  • Appleby (Cayman) Ltd. (Cayman Islands counsel)
  • Jingtian & Gongcheng LLP (PRC counsel)

🧩 Final Takeaway

Connect Biopharma secured essential, non-dilutive(*) funding through a discounted private placement to advance its clinical pipeline. While this provides a necessary cash runway, it comes at the cost of dilution to existing shareholders and reflects the high-stakes, capital-intensive nature of drug development. (*Note: It's dilutive in ownership, but "non-dilutive" in the sense it's not debt that needs to be repaid.)